Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28860292 | 0.87 | ALDH1A1 (0.63) | MEN1KMT2AMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL807418 | 0.86 | ALDH1A1 (0.58) | MEN1KMT2AMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL7303075 | 0.85 | ALDH1A1 (0.65) | MEN1KMT2AMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL5528296 | 0.85 | MAPK1 (0.49) | MEN1KMT2AMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL2498472 | 0.83 | MAPT (0.63) | MEN1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL27761620 | 0.83 | LMNA (0.52) | MEN1KMT2AMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL19381361 | 0.82 | MEN1 (0.44) | MEN1KMT2AMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL23705839 | 0.81 | ALDH1A1 (0.55) | MEN1KMT2AMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL13849368 | 0.81 | ALDH1A1 (0.55) | MEN1KMT2AMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL31091978 | 0.81 | ALDH1A1 (0.55) | MEN1KMT2AMAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017159484-A1 | 2,4-DIAMINOPHENOL DERIVATIVE, AND AGENT FOR INHIBITING AGGREGATION OF TAU AND/OR AMYLOID β | 学校法人同志社 | 2017-09-21 | — | — | WO | disclosed |
| US-20170166554-A1 | BETA-ARRESTIN-BIASED CANNABINOID CB1 RECEPTOR AGONISTS AND METHODS FOR MAKING AND USING THEM | THE UNIVERSITY OF NORTH CAROLINA AT GREENSBORO (US) | 2017-06-15 | — | — | US | disclosed |
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166554-A1 | BETA-ARRESTIN-BIASED CANNABINOID CB1 RECEPTOR AGONISTS AND METHODS FOR MAKING AND USING THEM | CNR1, CNR2, ARRB1 | MEN1 4098/4885KMT2A 3715/4885MAPT 3519/4885 |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | AVPR1B, AVPR1A, AVPR2 | MEN1 527/4885KMT2A 1662/4885MAPT 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.